Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.
Burke, GA Amos
Pediatr Blood Cancer
MetadataShow full item record
Carruthers, V., Barnett, S., Rees, R., Arif, T., Slater, O., Ramanujachar, R., Johnson, K., et al. (2022). Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.. Pediatr Blood Cancer https://doi.org/10.1002/pbc.29722
Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.
ONCOLOGY: BRIEF REPORT, infantile myofibroma, neonate, pharmacokinetics, therapeutic drug monitoring, vinblastine
External DOI: https://doi.org/10.1002/pbc.29722
This record's URL: https://www.repository.cam.ac.uk/handle/1810/336254